Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Int J Cancer. 2013 Jan 10;133(1):31–42. doi: 10.1002/ijc.27996

Table 1.

Selected list of TNFAIP8 interacting proteins identified by antibody microarray analysis

ID Symbol Fold Change1 P-value2 Entrez Gene Name Location Type(s)
P56159 GFRA1 2 4.00E-05 GDNF family receptor alpha 1 Plasma Membrane transmembrane receptor
P09874 PARP1 1.8 4.00E-05 poly (ADP-ribose) polymerase 1 Nucleus enzyme
Q01130 SRSF2 1.5 4.00E-06 serine/arginine-rich splicing factor 2 Nucleus transcription regulator
P52292 KPNA2 1.5 1.90E-04 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) Nucleus transporter
Q9UHI6 DDX20 1.4 1.90E-04 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 Nucleus transcription regulator
P18031 PTPN1 1.3 1.50E-04 protein tyrosine phosphatase, non-receptor type 1 Cytoplasm phosphatase
P24864 CCNE1 1.2 4.00E-05 cyclin E1 Nucleus transcription regulator
1

PC-3 cells were treated with TNFAIP8 siRNA (Si2 SiRNA/SiRNA) or a scrambled siRNA (ScrSiRNA/MM) and the proteomic profiles in the TNFAIP8 immune-complexes were identified by the antibody microarray analysis as described in Materials and Methods. Detailed list of all proteins is provided in Supporting Information Table 1. Fold change represents the ratio of largest of MM. Si, divided by smallest.

2

P-value is the significance of the difference between the two spots for MM and the two spots for SiRNA. All results shown above were found to be statistically significant even under the very stringent Bonferroni criterion to adjust for multiple testing.